PP-089 A new ultra short regimen with dexlansoprazole, moxifloxacin, amoxicillin, nitazoxanide, and doxycycline (DeMAND) in eradication of Helicobacter pylori: an open-label randomized clinical trial P.P. Basu 1,2 *, N. Krishnaswamy 2 , R. Korapati 2 , S. Tammisetti 2 , N.J. Shah 2 , H. Hampole 2 , T. Pacana 2 , C.C. Tang 2 . 1 Columbia University, New York, 2 North shore University Hospital at Forest Hills, NY, USA Objectives: Treatment failure for Helicobacter pylori (HP) is due to antimicrobial resistance and recrudescence. Traditional approach with multi-antimicrobials is complex, with long duration of therapy, resulting in poor compliance and numerous side effects. A newer therapeutic paradigm is evolving with shorter durations, salvage therapies, and sequential regimens. This study utilizes an ultra-short regimen for better compliance, minimal side effects and similar efficacy. Methods: Seventy-five (n = 75) dyspeptic patients of diverse ethnicity, mean age 36 years, underwent upper endoscopy with four quadrant antro-gastric biopsies with positive PCR and stool antigen for HP. All were randomized into three arms: DeMAND (n = 25): Dexlansoprozole 60mg, Moxifloxacin 400mg, Amoxicillin 1g, Doxycycline 100 mg daily and Nitazoxanide 500mg BID for four days; LOAD (n = 25): Levofloxacin 250mg, Omeprazole 40mg, and Doxycycline 100mg daily, with Alinia (nitazoxanide) 500mg BID for seven days; LAC (n = 25) with a standard regimen of Lansoprazole 15mg, Amoxicillin 1g, Clarithromycin 500mg BID for seven days. Exclusion: active bleeding, pregnancy, antimicrobial hypersensitivity, and use of antisecretory and antimicrobials within eight weeks. Results: 68/75 patients (90.7%) completed the study with seven (9%) dropouts. Side effects were minor rash, dizziness, bloating, diarrhea, and palpitations. The ITT analysis for 30 days post-therapy HP stool antigen test was negative in 19/25 patients (76%) for DeMAND, 22/25 (88%) for LOAD, and 18/25 (72%) for LAC, there was no significant difference in eradication rate amongst all groups (c 2 = 2.1, p = 0.36). Perprotocol analysis revealed no difference (c 2 = 2.4, p = 0.30) in eradication rate amongst DeMAND (19/23; 82.6%), LOAD (22/23; 95%), or LAC (18/22; 81%). Conclusions: The 4-day DeMAND regimen is well-tolerated and clinically comparable to LOAD and LAC therapy for the eradication of H. pylori. This novel ultra-short therapy may provide an additional cost benefit as well as patient acceptance. A larger trial warrants validation.
PP-090 A comparison of real-time PCR and PCR-RFLP methods for simultaneous identification of
Helicobacter pylori and clarithromycin resistance point mutations bacterial strains were found in the remaining 16 (9.76%) cases. Genotype of 5 (8.47%) strains were not detected. 39 (23.78%) resistant strains were detected by PCR-RFLP method which were identified as 15 (9.15%) A2143G, 15 (9.15%) A2142G and 9 (5.49%) mix strains. Conclusion: Results showed that Real-time PCR assay, has enough sensitivity to simultaneously identification of H. pylori and clarithromycin resistance in short time.
